AVTX- Avalo Therapeutics, Inc.

Insider activity in AVTX over the last quarter tilts toward selling: insiders offloaded a net 101,317 shares worth roughly $2.0M.

Classified under Biotechnology (Health Care sector), AVTX's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Neil Garry Arthur	190.3K	-	-
Other	Boyd Taylor	95.0K	-	-
Other	Doyle Mittie	51.8K	$1.04M	-
CFO	Sullivan Christopher Ryan	39.9K	$651.7K	-
Other	Riley Jennifer	37.0K	$725.6K	-

Buys and sells only

10 filings · page 14

Date	Insider	Role	Type	Shares	Price	Value	Chg%
Dec 4, 2017	Moscato Robert Jr.	COO	Buy	285	$1.77	$504.45	-
Nov 24, 2017	Armistice Capital, LLC56	Director, 10% Owner	Buy	45,200	$1.20	$54,190.28	+0.3%
Oct 16, 2017	Armistice Capital, LLC56	Director, 10% Owner	Buy	4,800	$1.08	$5,174.40	-
Sep 29, 2017	Armistice Capital, LLC56	Director, 10% Owner	Buy	6,883	$0.87	$5,986.15	-
Sep 28, 2017	Armistice Capital, LLC56	Director, 10% Owner	Buy	13,952	$0.80	$11,105.24	-
Sep 22, 2017	Armistice Capital, LLC56	Director, 10% Owner	Buy	14,660	$0.78	$11,494.05	-
Sep 20, 2017	Armistice Capital, LLC56	Director, 10% Owner	Buy	51,369	$0.75	$38,705.66	+0.3%
Sep 8, 2017	Armistice Capital, LLC56	Director, 10% Owner	Buy	4,299	$0.74	$3,198.84	-
Sep 1, 2017	Armistice Capital, LLC56	Director, 10% Owner	Buy	39,479	$0.76	$29,877.21	+0.2%
Aug 29, 2017	Armistice Capital, LLC56	Director, 10% Owner	Buy	113,649	$0.73	$83,062.10	+0.7%